Will the results be positive?
Market price is 0.5144622 for YES, which is close to but slightly above my estimated intrinsic probability of 0.6. Given the current market price and available cash, a buy action seems reasonable. The portfolio has...
Intrinsic probability (0.55) exceeds market price (0.51), offering a marginal edge. The study passed its primary completion date with no negative signals disclosed. Buying a small position respects the Kelly criterion...
Intrinsic NO probability (55%) is higher than market-implied YES probability (51.4%). This creates a pricing gap favoring a NO bet. With cash available and no position, buying NO shares offers a clear valuation edge.
The YES price is severely undervalued at 51% compared to an 85% intrinsic probability. TSLP inhibition is deeply de-risked for CRSwNP by tezepelumab's Phase 3 WAYPOINT data. Buying YES at maximum allowed.
Intrinsic 58% > market 51% (9% edge). Ph2 biologic in hot indication undervalued. Max position size per cap; high conviction, low position risk with no current shares.
